New Data Show Use of Abbott's FreeStyle ® Libre System Reduces All-Cause, Diabetic Ketoacidosis-Related Hospitalization Rates and Acute Diabetes Events
(Source: Abbott.com)
Source: Abbott.com - June 16, 2020 Category: Pharmaceuticals Source Type: news
Abbott's FreeStyle ® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards
- FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning (Source: Abbott.com)
Source: Abbott.com - June 15, 2020 Category: Pharmaceuticals Source Type: news
New Late-Breaking Data Show Use of Abbott's FreeStyle ® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not
- Real-world data(1) presented at the American Diabetes Association 80th Scientific Sessions suggest people with type 2 diabetes can achieve similar outcomes to adding insulin therapy for both long-acting insulin or non-insulin users (Source: Abbott.com)
Source: Abbott.com - June 13, 2020 Category: Pharmaceuticals Source Type: news
Abbott Declares 386th Consecutive Quarterly Dividend
(Source: Abbott.com)
Source: Abbott.com - June 12, 2020 Category: Pharmaceuticals Source Type: news
Abbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests
- Urgent care clinic study shows ID NOW test performance of ≥94.7% positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) compared to lab-based PCR reference tests (Source: Abbott.com)
Source: Abbott.com - May 21, 2020 Category: Pharmaceuticals Source Type: news
Abbott Announces Contract to Supply Millions of IgG Lab-Based Antibody Tests to the UK Government
- Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing (Source: Abbott.com)
Source: Abbott.com - May 21, 2020 Category: Pharmaceuticals Source Type: news
Abbott Provides Update on ID NOW ™
(Source: Abbott.com)
Source: Abbott.com - May 14, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity ™ m System
- Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March (Source: Abbott.com)
Source: Abbott.com - May 12, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity ™ i System
- Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began (Source: Abbott.com)
Source: Abbott.com - May 11, 2020 Category: Pharmaceuticals Source Type: news
Research from University of Washington Demonstrates High Performance of Abbott's SARS-CoV-2 Antibody Blood Test
- Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began (Source: Abbott.com)
Source: Abbott.com - May 8, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives Health Canada Authorization under Interim Order to Use FreeStyle ® Libre System for Hospitalized Patients During COVID-19 Pandemic
-- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE) (Source: Abbott.com)
Source: Abbott.com - April 27, 2020 Category: Pharmaceuticals Source Type: news
Abbott Reports First-Quarter 2020 Results
- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent (Source: Abbott.com)
Source: Abbott.com - April 16, 2020 Category: Pharmaceuticals Source Type: news
Abbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow
- This adds to Abbott's previously announced COVID-19 molecular tests: the m2000 ™ lab-based test and ID NOW™ rapid point-of-care test (Source: Abbott.com)
Source: Abbott.com - April 15, 2020 Category: Pharmaceuticals Source Type: news
Abbott Announces Virtual Attendance at Annual Meeting of Shareholders
(Source: Abbott.com)
Source: Abbott.com - April 14, 2020 Category: Pharmaceuticals Source Type: news
Abbott's TriClip ™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
- CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition (Source: Abbott.com)
Source: Abbott.com - April 9, 2020 Category: Pharmaceuticals Source Type: news
